2020年9月10日 · Biomarkers are key in distinguishing between high-risk and indolent cases, allowing the latter to avoid unnecessary initial treatment.

2024年9月12日 · Research offers promising insights into the ideal frontline therapies for mantle cell lymphoma (MCL), but there are continued unmet needs in the relapsed/refractory setting, blood cancer ...

2023年1月31日 · Drs Peter Martin and Brad Kahl discuss autologous stem cell transplantation for mantle cell lymphoma, the TRIANGLE trial results, and the transition toward use of Bruton tyrosine kinase inhibitors.

2023年2月28日 · She serves as a lymphoma program director and director of lymphoma research in the Division of Hematology Oncology and has a particular interest in aggressive B-cell lymphomas, including mantle ...

2022年6月4日 · Results from the phase 3 SHINE trial show that adding ibrutinib to standard therapy delays progression by 50% in older patients with mantle cell lymphoma.

2016年1月19日 · A better understanding of the biology of mantle cell lymphoma and improved treatments in the past 2 decades make a cure for this disease a definite possibility, say leaders in the field.

The European Mantle Cell Lymphoma Network directly tested the importance of an HDAC-containing regimen and reported preliminary results of a trial of R-CHOP versus R-CHOP alternating with ...

2023年4月27日 · Drs Peter Martin and Eric Hsi have a thought-provoking discussion on key topics in the pathology of mantle cell lymphoma, including biopsies, diagnostic markers, and what the future holds for ...

2013年11月13日 · The US Food and Drug Administration (FDA) today approved ibrutinib (Imbruvica, Pharmacyclics, Janssen Biotech), a "breakthrough" drug for mantle cell lymphoma (MCL) that has been hailed as a ...

2023年1月31日 · Drs Peter Martin and Eva Hoster discuss minimal residual disease, the Mantle Cell Lymphoma International Prognostic Index, and newer variable additions and their role in understanding recent findings.